Top Markets
#1 DogBull DogBull +107.86%
#2 MarsCoin MarsCoin +53.66%
#3 ADO Protocol ADO Protocol +52.12%
#4 Siacoin Siacoin +48.12%
#5 Nockchain Nockchain +28.78%
#6 The Bitcoin Bull The Bitcoin Bull +22.78%
#7 Ontology Gas Ontology Gas +21.15%
#8 UnifAI Network UnifAI Network +19.42%
#9 Apertum Apertum +19.26%
#10 Useless Coin Useless Coin +18.08%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Jiangsu Recbio Technology Co., Ltd. Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd.

2179
Rank in Stocks #15662
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company... Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portion of its pipeline is dedicated to combating human papillomavirus (HPV)-related diseases, including cervical cancer and genital warts. Its most advanced candidate, REC603, is a recombinant 9-valent HPV vaccine currently undergoing Phase III clinical trials. Additionally, two bivalent HPV vaccines, REC601 and REC602, are progressing through Phase I trials. Further early-stage development includes the quadrivalent REC604a and 9-valent REC604b recombinant HPV vaccines, both in preclinical stages. Beyond HPV, the company boasts a diverse pipeline addressing other infectious diseases. Its COVID-19 efforts include ReCOV, a recombinant vaccine candidate in Phase II/III trials, and the preclinical messenger RNA (mRNA) candidate, R520A. Other preclinical projects target various conditions, such as the recombinant shingles vaccine REC610, the virus-vectored adult tuberculosis vaccine REC607, and its recombinant counterpart REC606. Also in preclinical development are the recombinant quadrivalent influenza vaccine REC617 and the recombinant quadrivalent hand-foot-mouth disease vaccine REC605. Established in 2011, Recbio Technology maintains its headquarters in Taizhou, People's Republic of China.
Share Price
$0.63963115
Last synced: 2026-08-26
Market Cap
$339.16M
Change (1 day)
0.00%
Change (1 year)
-35.23%
Country
CN
Trade Jiangsu Recbio Technology Co., Ltd. (2179)

Category

Healthcare
Number of shares outstanding for Jiangsu Recbio Technology Co., Ltd. (2179)
Number of shares outstanding as of September 2026: 0
According to Jiangsu Recbio Technology Co., Ltd. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of September 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Jiangsu Recbio Technology Co., Ltd. (2179) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH